CompletedNCT02824055
A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics
Medication studyAges 18–50United States
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- Garden Grove and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: June 27, 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 33
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT02824055
- Official title
Show the full official title
A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics
Get this study by email
Recruitment & locations
CompletedGarden Grove · Glendale · St Louis
Questions about this study
Who is behind this study?
The study sponsor is Hoffmann-La Roche.
Did this study involve medication?
Yes. The study involved medication, including Placebo and RO5545965.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia